In oncology, standards of care evolve rapidly. MEDExpansion explains why clinical strategy must anticipate future benchmarks from the earliest development phases
MEDExpansion explores how early strategic positioning can strengthen oncology clinical trials and anticipate evolving standards of care throughout development
MEDExpansion explains why defining the right medical need early is essential to build a strong oncology development strategy and guide clinical decision-making
ADCs were designed to selectively kill biomarker-positive cancer cells, but real-world results are complex. Learn why early clinical analysis is key to balancing efficacy, biomarker
ADCs disrupt the “biomarker = efficacy” model in precision medicine. Learn why payload, linker, and biomarker thresholds shape tumor selection, Phase 2 strategy, and clinical
Oncology is shifting fast. Base your clinical strategy on predictive cell testing, not animal studies. Identify the right tumors early and avoid dead ends.
The biotome may impact response to immunotherapy. Could it become a new predictive biomarker in oncology? A look at recent scientific insights.
FDA’s exemption challenges phase 2 design in oncology. Should we move away from animal models and focus on early, cell-level clinical analysis?
Good news for animal welfare: the FDA has eased preclinical requirements
This simplified case study is inspired by real-world challenges
Immunotherapies have transformed cancer prognostic, and they’re reshaping early-phase clinical development too, demanding new strategies.
Your pitch to investors is about your innovation. Great ! But what if they are expecting something else (the CMO speaking) ?
In oncology, what if you design your phase 2 and the trajectory to phase 3 …. starting already from the in vitro stage ?
Can the microbiome silently impact immuno-oncology trials? Discover how it may influence your phase 1/2 study outcomes without being on your radar.
One new EMA/FDA approval EVERY 5 MONTHS. This means faster changes in standards of care, and in future phase 3 comparators.
Immunotherapy is no longer a last-resort option. It is now integrated earlier into cancer treatment, but at what cost for molecules in development?
